Kinematic-based BoNT-A Injections for Bilateral ET
Kinematic-based BoNT-A Injections for Bilateral ET
The primary objective is to study the efficacy of botulinum toxin type A (Xeomin®) injected
 utilizing kinematically-based injection parameters for the treatment of upper extremity
 essential tremor (ET). Additional objectives are to study the benefit of kinematic assessment
 tools in determining injection parameters and to study the composition of tremor using
 kinematics.
Inclusion Criteria:

 -  Consenting male and female participants

 -  Diagnosis of 'definite essential tremor' in accordance with the TRIG criteria
 including: ET individuals diagnosed with upper limb tremor in their motor dominant and
 non-dominant hands

 -  Stable ET medication management for the 3 month duration prior to their enrollment in
 the study

 -  Participants who are botulinum toxin naïve for tremor management

 -  Patients will be screened for pregnancy by the physician

 Exclusion Criteria:

 -  History of stroke

 -  Muscle weakness or any related compartmental muscle syndrome

 -  Smoking

 -  History of ALS or Myasthenia Gravis

 -  Offending medications (Lithium, valproate, steroids, amiodarone, beta-adrenergic
 agonists (e.g. salbutamol)

 -  Persons prescribed zonisamide

 -  History of allergic or side effect reaction to botulinum toxin

 -  Contraindications per the Xeomin® drug monograph

 -  Women reporting that they are pregnant